Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Johanne
J
Silvain
Gilles
G
Montalescot
D054058:Acute Coronary Syndrome / Q000401:mortality / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D017984:Enoxaparin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006629:Hirudins; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D010446:Peptide Fragments / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin; D006629:Hirudins; D010446:Peptide Fragments; D011134:Polysaccharides; D011994:Recombinant Proteins; D006493:Heparin; D000077425:Fondaparinux; C074619:bivalirudin